RESUMO
OBJECTIVE: The objective of this study was to determine neonatal outcomes in preterm operative vaginal delivery given the current paucity of data available to guide clinicians. STUDY DESIGN: A retrospective review of 64 cases was conducted, and neonatal outcomes were compared to spontaneous vaginal deliveries in similar gestations. The primary outcomes studied were death and occurrence of intraventricular haemorrhage. Secondary outcomes included admission to NICU, Apgar < 3 at 5 min, ventilation requirement, jaundice requiring treatment, culture-proven sepsis and necrotising enterocolitis. The study was conducted in a stand-alone maternity unit of approximately 9000 deliveries per year. RESULTS AND CONCLUSIONS: We concluded that although vacuum delivery is avoided in preterm infants, outcomes were similar to forceps deliveries of similar gestations.
Assuntos
Traumatismos do Nascimento/epidemiologia , Hemorragia Cerebral/epidemiologia , Parto Obstétrico/efeitos adversos , Hospitalização/estatística & dados numéricos , Nascimento Prematuro , Traumatismos do Nascimento/etiologia , Hemorragia Cerebral/etiologia , Feminino , Humanos , Forceps Obstétrico/efeitos adversos , Segurança do Paciente , Mortalidade Perinatal , Gravidez , Resultado da Gravidez/epidemiologia , Estudos Retrospectivos , Vácuo-Extração/efeitos adversosRESUMO
The enzyme kinetics of the amide ligase MurE, a cell wall biosynthesis enzyme, from Pseudomonas aeruginosa were determined using the synthesized nucleotide substrate UDP-MurNAc-Ala-Glu (uridine 5'-diphosphoryl N-acetylmuramoyl-L-alanyl-D-glutamate). When coupled to a competitive bio-panning technique using a M13 phage display library encoding approximately 2.7 x 10(9) random peptide permutations and the specific substrates meso-A2pm (meso-diaminopimelic acid) and ATP, a peptide inhibitor of MurE was identified. The MurEp1 dodecamer selected and synthesized inhibited MurE ATPase activity with an IC(50) value of 500 microM. The inhibition was shown to be time-dependent and was reversed by the addition of meso-A2pm or UDP-MurNAc-Ala-Glu during the pre-incubation step. Kinetic analysis defined MurEp1 as a mixed inhibitor against both substrates with K(i) values of 160 and 80 microM respectively. MurEp1 was found to interfere in meso-A2pm and UDP-MurNAc-Ala-Glu binding necessary for amide bond formation. Modelling of Ps. aeruginosa MurE and docking of MurEp1 on the Ps. aeruginosa MurE surface indicated that MurEp1 binds at the juxtaposition of both meso-A2pm- and UDP-MurNAc-Ala-Glu-binding sites in the closed conformational state of the enzyme. Identification of the MurEp1 residues involved in MurE binding and inhibition will allow the development of a novel class of inhibitors having a novel mode of action against MurE.
Assuntos
Proteínas de Bactérias/antagonistas & inibidores , Proteínas de Bactérias/química , Oligopeptídeos/química , Peptídeo Sintases/antagonistas & inibidores , Peptídeo Sintases/química , Peptídeos/química , Pseudomonas aeruginosa/enzimologia , Sequência de Aminoácidos , Proteínas de Bactérias/metabolismo , Sítios de Ligação , Dipeptídeos/química , Cinética , Modelos Moleculares , Dados de Sequência Molecular , Oligopeptídeos/metabolismo , Peptídeo Sintases/metabolismo , Peptídeos/metabolismo , Conformação Proteica , Pseudomonas aeruginosa/metabolismo , Uridina Difosfato Ácido N-Acetilmurâmico/análogos & derivados , Uridina Difosfato Ácido N-Acetilmurâmico/químicaRESUMO
Paramedic tracheal intubation has been practised in the UK for more than 20 years and is currently a core skill for paramedics. Growing evidence suggests that tracheal intubation is not the optimal method of airway management by paramedics and may be detrimental to patient outcomes. There is also evidence that the current initial training of 25 intubations performed in-hospital is inadequate, and that the lack of ongoing intubation practice may compound this further. Supraglottic airway devices (eg, laryngeal mask airway), which were not available when extended training and paramedic intubation was first introduced, are now in use in many ambulance services and are a suitable alternative prehospital airway device for paramedics.
Assuntos
Pessoal Técnico de Saúde , Serviços Médicos de Emergência/normas , Medicina Baseada em Evidências , Intubação Intratraqueal/normas , Comitês Consultivos , Pessoal Técnico de Saúde/educação , Ambulâncias , Reanimação Cardiopulmonar/métodos , Competência Clínica , Traumatismos Craniocerebrais/terapia , Serviços Médicos de Emergência/métodos , Humanos , Medição de Risco , Resultado do Tratamento , Reino UnidoRESUMO
The emerging dual threats of underaged drinking (UAD) and prescription drug misuse (PDM) require sustained prevention efforts across multiple levels of interventions. In response to the continuing proliferation of UAD and PDM among youth and young adults, the Substance Abuse and Mental Health Services Administration (SAMHSA) developed the Partnerships for Success (PFS) program. Across five cohorts funded from 2012 to 2016, PFS created linkages between health care providers, treatment and prevention services providers, government agencies, and nonprofit organizations for the delivery of multiple sets of services (e.g., prevention education, community activities, screening) targeted toward UAD and PDM. This paper reports on the impact of the PFS program on reductions in ethanol and prescription drug poisoning exposures as reported from data in the National Poisoning Data System (NPDS). Across 35 States, communities targeted by PFS interventions were compared to non-targeted communities using a non-equivalent comparison groups design and propensity score weighting. Using propensity-weighted, multilevel latent growth modeling, steeper reductions in ethanol and prescription drug poisoning exposure call rates were observed in States which had a higher proportion of communities participating in PFS. Grantee-level longitudinal analogs to Cohen's d effect sizes ranged from -0.24 to -0.97, whereas PFS' effects on individual communities (net of Statewide effects) were negligible. The study serves as a unique exemplar of using the NPDS to extract community-level intervention effects that might otherwise be "hidden" within epidemiological data while underscoring the cumulative effects of PFS' community-level efforts in stemming the tide on underaged drinking and prescription drug misuse.
Assuntos
Analgésicos Opioides/intoxicação , Antidepressivos/intoxicação , Depressores do Sistema Nervoso Central/intoxicação , Estimulantes do Sistema Nervoso Central/intoxicação , Overdose de Drogas/epidemiologia , Etanol/intoxicação , Promoção da Saúde , Hipnóticos e Sedativos/intoxicação , Acidentes de Trânsito/mortalidade , Adolescente , Adulto , Criança , Dirigir sob a Influência/estatística & dados numéricos , Feminino , Humanos , Análise de Séries Temporais Interrompida , Masculino , Intoxicação/epidemiologia , Uso Indevido de Medicamentos sob Prescrição/prevenção & controle , Transtornos Relacionados ao Uso de Substâncias/prevenção & controle , Transtornos Relacionados ao Uso de Substâncias/terapia , Consumo de Álcool por Menores/prevenção & controle , Estados Unidos/epidemiologia , United States Substance Abuse and Mental Health Services Administration , Adulto JovemRESUMO
BACKGROUND: To develop antibacterial agents having novel modes of action against bacterial cell wall biosynthesis, we targeted the essential MurF enzyme of the antibiotic resistant pathogen Pseudomonas aeruginosa. MurF catalyzes the formation of a peptide bond between D-Alanyl-D-Alanine (D-Ala-D-Ala) and the cell wall precursor uridine 5'-diphosphoryl N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-diaminopimelic acid (UDP-MurNAc-Ala-Glu-meso-A2pm) with the concomitant hydrolysis of ATP to ADP and inorganic phosphate, yielding UDP-N-acetylmuramyl-pentapeptide. As MurF acts on a dipeptide, we exploited a phage display approach to identify peptide ligands having high binding affinities for the enzyme. RESULTS: Screening of a phage display 12-mer library using purified P. aeruginosa MurF yielded to the identification of the MurFp1 peptide. The MurF substrate UDP-MurNAc-Ala-Glumeso-A2pm was synthesized and used to develop a sensitive spectrophotometric assay to quantify MurF kinetics and inhibition. MurFp1 acted as a weak, time-dependent inhibitor of MurF activity but was a potent inhibitor when MurF was pre-incubated with UDP-MurNAc-Ala-Glu-meso-A2pm or ATP. In contrast, adding the substrate D-Ala-D-Ala during the pre-incubation nullified the inhibition. The IC50 value of MurFp1 was evaluated at 250 microM, and the Ki was established at 420 microM with respect to the mixed type of inhibition against D-Ala-D-Ala. CONCLUSION: MurFp1 exerts its inhibitory action by interfering with the utilization of D-Ala-D-Ala by the MurF amide ligase enzyme. We propose that MurFp1 exploits UDP-MurNAc-Ala-Glu-meso-A2pm-induced structural changes for better interaction with the enzyme. We present the first peptide inhibitor of MurF, an enzyme that should be exploited as a target for antimicrobial drug development.
Assuntos
Proteínas de Bactérias/antagonistas & inibidores , Parede Celular/enzimologia , Inibidores Enzimáticos/farmacologia , Biblioteca de Peptídeos , Pseudomonas aeruginosa/enzimologia , Sequência de Aminoácidos , Proteínas de Bactérias/química , Proteínas de Bactérias/isolamento & purificação , Proteínas de Bactérias/metabolismo , Vias Biossintéticas , Parede Celular/química , Parede Celular/efeitos dos fármacos , Cinética , Dados de Sequência Molecular , Pseudomonas aeruginosa/química , Pseudomonas aeruginosa/efeitos dos fármacosRESUMO
Antimicrobial resistance has been reported to represent a growing threat to both human and animal health, and concerns have been raised around levels of antimicrobial usage (AMU) within the livestock industry. To provide a benchmark for dairy cattle AMU and identify factors associated with high AMU, data from a convenience sample of 358 dairy farms were analysed using both mass-based and dose-based metrics following standard methodologies proposed by the European Surveillance of Veterinary Antimicrobial Consumption project. Metrics calculated were mass (mg) of antimicrobial active ingredient per population correction unit (mg/PCU), defined daily doses (DDDvet) and defined course doses (DCDvet). AMU on dairy farms ranged from 0.36 to 97.79 mg/PCU, with a median and mean of 15.97 and 20.62 mg/PCU, respectively. Dose-based analysis ranged from 0.05 to 20.29 DDDvet, with a median and mean of 4.03 and 4.60 DDDvet, respectively. Multivariable analysis highlighted that usage of antibiotics via oral and footbath routes increased the odds of a farm being in the top quartile (>27.9 mg/PCU) of antimicrobial users. While dairy cattle farm AMU appeared to be lower than UK livestock average, there were a selection of outlying farms with extremely high AMU, with the top 25 per cent of farms contributing greater than 50 per cent of AMU by mass. Identification of these high use farms may enable targeted AMU reduction strategies and facilitate a significant reduction in overall dairy cattle AMU.
Assuntos
Anti-Infecciosos/uso terapêutico , Indústria de Laticínios , Fazendas , Animais , Bovinos , Humanos , Reino UnidoAssuntos
Agricultura/tendências , Bancos de Espécimes Biológicos , Produtos Agrícolas , Sementes , Iraque , Pesquisa/tendências , Síria , GuerraAssuntos
Geologia/métodos , Arqueologia , Evolução Biológica , Cronologia como Assunto , Clima , Ecossistema , Fósseis , Geologia/economia , Paleontologia , Fatores de TempoAssuntos
Ebolavirus/imunologia , Doença pelo Vírus Ebola/prevenção & controle , Macaca fascicularis/imunologia , Vacinas Virais/imunologia , Adenoviridae/genética , Adenoviridae/imunologia , Adenoviridae/fisiologia , Animais , Vetores Genéticos/genética , Vetores Genéticos/imunologia , Vetores Genéticos/fisiologia , Doença pelo Vírus Ebola/imunologia , Humanos , Fatores de Tempo , Vacinas Virais/administração & dosagemAssuntos
Síndrome Respiratória Aguda Grave/epidemiologia , Animais , Antivirais/farmacologia , China/epidemiologia , Doenças Transmissíveis Emergentes/epidemiologia , Doenças Transmissíveis Emergentes/mortalidade , Doenças Transmissíveis Emergentes/prevenção & controle , Planejamento em Saúde , Humanos , Mutação , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave/genética , Síndrome Respiratória Aguda Grave/mortalidade , Síndrome Respiratória Aguda Grave/prevenção & controle , Vacinas ViraisRESUMO
The lipodystrophies are a heterogeneous group of disorders of adipose tissue associated with insulin resistance. The sporadic form of partial lipodystrophy, characterised by fat loss from the face and upper body, is associated with complement abnormalities and mesangiocapillary glomerulonephritis type 2 (MCGN II) and the conditions are thought to have a shared autoimmune aetiology. We present the first case of the rare familial form of partial lipodystrophy, caused by a mutation in the LMNA gene, associated with MCGN II. This suggests that partial lipodystrophy of both the sporadic and familial subtypes may predispose to this condition and that the observed renal and complement abnormalities may be secondary to other factors associated with lipodystrophy.
Assuntos
Glomerulonefrite Membranoproliferativa/complicações , Lipodistrofia/complicações , Lipodistrofia/genética , Adulto , Diabetes Mellitus Tipo 2/complicações , Feminino , Predisposição Genética para Doença , Glomerulonefrite Membranoproliferativa/patologia , Humanos , Lamina Tipo A/genética , Mutação , SíndromeRESUMO
AIMS: This study aimed to (i) describe methadone dosing before, during and after pregnancy, (ii) to compare the incidence of neonatal abstinence syndrome (NAS) between those with dose decreases and those with steady or increasing doses and (iii) to describe prescribed medication use among opioid-dependent pregnant women. DESIGN: Prospective cohort study. SETTING: Two Irish tertiary care maternity hospitals. PARTICIPANTS: A total of 117 pregnant women on methadone maintenance treatment (MMT) recruited between July 2009 and July 2010. MEASUREMENTS: Electronic dispensing records from addiction clinics and the Primary Care Reimbursement Service were used to determine methadone doses and dispensed medications in the year preceding and the month following delivery. The Finnegan score was used to determine need for medical treatment of NAS. FINDINGS: Of the 117 participants, sufficient dosing data were available for 89 women treated with MMT throughout pregnancy; 36 (40.4%) had their dose decreased from a mean pre-pregnancy dose of 73.3 mg [standard deviation (SD) 25.5] to a third-trimester dose of 58.0 mg (SD 26.0). The corresponding figures for those with increased doses (n = 31, 34.8%) were 70.7 mg (SD 25.3) and 89.7 mg (SD 21.0), respectively. The incidence of medically treated NAS did not differ between dosage groups. Antidepressants were dispensed for 29 women (25.7%) during pregnancy, with the rate decreasing from pre-pregnancy to postpartum. Benzodiazepines were prescribed for 43 women (38.0%). CONCLUSION: In the Irish health service, opioid-dependent women frequently have their methadone dose decreased during pregnancy but this does not appear to affect the incidence of the neonatal abstinence syndrome in their babies.